Press Releases August 10, 2026 05:00 PM

Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference

Prestige Consumer Healthcare to present at Canaccord Genuity Annual Growth Conference

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
PBH

Prestige Consumer Healthcare Inc. announced that key executives will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be webcast live and archived on the company's website. Prestige markets a diverse portfolio of consumer healthcare brands in the US, Canada, Australia, and other international markets.

Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference
PBH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Prestige Consumer Healthcare executives to share insights at a major growth conference, potentially increasing investor visibility.
  • Live webcast and replay access broaden availability of the company's presentation to investors and analysts.
  • The company has a broad and diverse portfolio of established consumer healthcare brands across multiple international markets.

TARRYTOWN, N.Y., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Christine Sacco, CFO and COO, and Phil Terpolilli, VP, Investor Relations, Treasury, & Business Development will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday August 12, 2026 at 10:00 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:

https://ir.prestigebrands.com/events-presentations/events

For those unable to participate during the live webcast, a replay option will be available on the Company’s website following the event.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, as well as Hydralyte® rehydration products and the Dermal Therapy® line of therapeutic skin care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.


Risks

  • Market reception to the presentation content is uncertain and may not influence stock price positively.
  • Competition in the consumer healthcare sector could impact Prestige's growth prospects.
  • International market and regulatory risks remain relevant given the company's presence in multiple geographic regions.

More from Press Releases

Sysco Announces Pricing of Common Stock Offering Sep 15, 2026 Einride and Lidl Launch First Autonomous Cab-less Truck on German Public Road Sep 15, 2026 Piedmont Realty Trust Announces Pricing of $200,000,000 Exchangeable Senior Notes Offering Sep 14, 2026 VPG Foil Resistors Partners with Source Technologi to Expand Footprint in India’s Aerospace & Defense, Telecom, and Semiconductor Sectors Sep 14, 2026 IHT RECEIVES NYSE-AMERICAN APPROVAL FOR COMPLIANCE PLAN; REVERSE MERGER DISCUSSIONS CONTINUE Sep 14, 2026